Identification of patterns of abnormalities seen on DaTscan™ SPECT imaging in patients with non-Parkinson’s movement disorders

References

• Nuvoli S, Madeddu AS, Brain G. SPECT with perfusion radiopharmaceuticals and dopaminergic system radiocompounds in dementia disorders. Current Alzheimer Research. 2017. Available from: http://www.eurekaselect.com/146511/article. Accessed April 3, 2019.
   Google Scholar
• Marsala SZ, Pistacchi M, Gioulis M, Ferracci F, Capus L. Clinical and imaging study of isolated and mixed rest and action tremor-essential tremor versus Parkinson’s disease. Ann Indian Acad Neurol. 2017;20(2):138–141. doi:10.4103/aian.AIAN_497_16
   Web of Science ®Google Scholar
• Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012;83(6):620–628. doi:10.1136/jnnp-2011-301695
   Web of Science ®Google Scholar
• Cummings J, Fine M, Grachev I, et al. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscanâ„¢). Ajmc. Available from: https://www.ajmc.com/journals/supplement/2014/a477_mar14_datscan/a440_mar14_datscan_s97tos109. Accessed April 3, 2019.
   Google Scholar
• Papathanasiou N, Rondogianni P, Chroni P, et al. Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies. Ann Nucl Med. 2012;26(3):234–240. doi:10.1007/s12149-011-0564-1
   Web of Science ®Google Scholar
• Djang DSW, Janssen MJR, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123i-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154–163. doi:10.2967/jnumed.111.100784
   PubMed Web of Science ®Google Scholar
• Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22(16):2346–2351. doi:10.1002/mds.21710
   Web of Science ®Google Scholar
• Broski SM, Hunt CH, Johnson GB, Morreale RF, Lowe VJ, Peller PJ. Structural and functional imaging in parkinsonian syndromes. RadioGraphics. 2014;34(5):1273–1292. doi:10.1148/rg.345140009
   Web of Science ®Google Scholar
• Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord. 2006;21(4):510–514. doi:10.1002/mds.20748
   PubMed Web of Science ®Google Scholar
• Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123 I]FP-CIT SPECT. Mov Disord. 2009;24(4):500–508. doi:10.1002/mds.22108
   PubMed Web of Science ®Google Scholar
• Nuvoli S, Spanu A, Piras MR, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. Medicine (Baltimore). 2017;96(21):e6967. doi:10.1097/MD.0000000000006967
   Web of Science ®Google Scholar
• Nuvoli S, Palumbo B, Malaspina S, Madeddu G, Spanu A. 123I-Ioflupane SPET and 123I-MIBG in the Diagnosis of Parkinson’s Disease and Parkinsonian Disorders and in the Differential Diagnosis between Alzheimer’s and Lewy’s Bodies Dementias. J Nucl Med. 2018;21(1):60–68. doi:10.1967/s002449910707
   Web of Science ®Google Scholar
• McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305–313. doi:10.1016/S1474-4422(07)70057-1
   PubMed Web of Science ®Google Scholar
• Walker Z, Jaros E, Walker RWH, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78(11):1176–1181. doi:10.1136/jnnp.2006.110122
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Booij J, Reneman L, Habraken JBA, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–869. doi:10.1007/s002590000279
   PubMedGoogle Scholar
• Palumbo B, Fravolini ML, Nuvoli S, et al. Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson’s disease by 123I-FP-CIT brain SPECT. Eur J Nucl Med Mol Imaging. 2010;37(11):2146–2153. doi:10.1007/s00259-010-1481-6
   Web of Science ®Google Scholar
• Henderson T. Idiopathic Parkinson: diagnosis of the deceptive | neurology times. Available from:https://www.neurologytimes.com/articles/idiopathic-parkinson-diagnosis-deceptive. Accessed April 3, 2019.
   Google Scholar
• Benito-León J, Louis ED, Bermejo-Pareja F. Neurological disorders in central spain study group. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80(4):423–425. doi:10.1136/jnnp.2008.147223
   PubMed Web of Science ®Google Scholar
• Gayed I, Joseph U, Fanous M, et al. The impact of DaTscan in the diagnosis of Parkinson disease. Clin Nucl Med. 2015;40(5):390–393. doi:10.1097/RLU.0000000000000766
   Web of Science ®Google Scholar